Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Evaluation of the PillCam™ Colon Capsule Endoscopy (PCCE) in Detection & Classification of Ulcerative Colitis

29. Juli 2019 aktualisiert von: Medtronic - MITG
To evaluate the ability of the PillCam® Colon Capsule Endoscope to detect and classify Ulcerative colitis

Studienübersicht

Status

Abgeschlossen

Detaillierte Beschreibung

Ulcerative colitis (UC) is a disorder of unknown origin that may be characterized by acute and chronic inflammation of the colon. The extent of the colonic mucosal inflammation varies among individuals, but the disease almost always involves the rectum. Ulcerative colitis has required evaluation by colonoscopy to determine the extent and severity of the disease. The PillCam platform offers an alternative approach for endoscopic visualization of the colon using capsule endoscopy, a swallowable device which contains imagers, light sources, a power source and a RF transmitter. Advantages of the PillCam platform include the elimination of the need for conscious sedation, the minimally invasive, painless nature of the exam, and the ability to pursue normal daily activities immediately following the procedure . Furthermore, compared to standard colonoscopy, the PillCam platform may be more readily accepted by the subjects, thereby improving subjects' willingness to undergo a diagnostic evaluation of the colon.

The PillCam® SB capsule (formerly M2A® Capsule) that was FDA-approved in August 2001 for small bowel evaluation has been ingested to date by more than 700,000 people worldwide and is well accepted by patients and physicians as well as the professional societies. However, adequate visualization of the colon cannot be achieved with the standard PillCam™ SB capsule because of the anatomical and physiological properties of the colon which are significantly different than the small bowel. Moreover, other issues that limit the evaluation of the colonic mucosa by the standard PillCam™ SB procedure include an unsatisfactory level of colon cleanliness and slow progression of the PillCam™ SB capsule through the colon during the desired examination time. Therefore, the development and introduction of a specially designed, customized colon capsule combined with a dedicated capsule colonoscopy procedure protocol will allow for more efficient evaluation of the colonic mucosa. Further details of the PillCam® Colon Capsule Endoscope (PCCE) can be found in the device description section.

In previous studies, the PillCam colon platform has been shown to be safe and to be able to demonstrate colon polyps and cancers. This study is an extension to a trial evaluating the use of PCCE in ulcerative colitis that has already been completed in Hong Kong (n=40). This study is designed to assess the ability of the capsule to accurately detect inflammatory lesions and thus classifying the extent and severity of disease in subjects with ulcerative colitis in comparison to traditional colonoscopy.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

97

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Hong Kong, Hongkong
        • Chinese university of Hong Kong, Princes of Walses Hospital
      • Singapore, Singapur, 119074
        • Department of Medicine, National University Hospital
      • Taipei, Taiwan
        • Department of Internal Medicine & Health Management Center, National Taiwan University Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease

The study population will consist of subjects who fulfill all the inclusion criteria and none of the exclusion criteria.

Beschreibung

Inclusion Criteria:

  • Subjects 18-70
  • Suspected or known ulcerative colitis patients

Exclusion Criteria:

  • Subject has dysphagia
  • Subject has congestive heart failure
  • Subject who can not tolerate bowel preparation
  • Poor bowel preparation
  • Subject has renal insufficiency
  • Subject is known or is suspected to suffer from intestinal obstruction.
  • Subject has a cardiac pacemaker or other implanted electro-medical devices.
  • Subject is pregnant
  • Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
  • Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
  • Subject has any condition, which precludes compliance with study and/or device instructions.
  • Subject suffers from life threatening conditions
  • Subject is currently participating in another clinical study
  • Subject has constipation (less than 3 bowel movements/week)
  • Subject has known slow gastric emptying time

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
A
Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Agreement level between capsule and colonoscopy in classifying colitis into the above (see section 3.1) categories.
Zeitfenster: within 7 days
within 7 days

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Number, type and severity of adverse events with both PCCE and standard colonoscopy
Zeitfenster: Within 7 days
Within 7 days
Accuracy parameters for detecting active UC
Zeitfenster: within 7 days
within 7 days
Disease severity scoring index for both PCCE and .standard colonoscopy
Zeitfenster: within 7 days
within 7 days
Colon cleansing level score for both PCCE and standard colonoscopy.
Zeitfenster: within 7 days
within 7 days
Grading of the bubbles interference at the colon for PCCE.
Zeitfenster: Within 7 days
Within 7 days
Percentage of excreted colon capsules
Zeitfenster: Within 7 Days
Within 7 Days
PCCE transit time from ingestion to excretion and colon transit time
Zeitfenster: Within 7 Days
Within 7 Days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Josef Sung, Prof., Chinese University of Hong Kong

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. April 2007

Primärer Abschluss (Tatsächlich)

1. Februar 2010

Studienabschluss (Tatsächlich)

1. März 2010

Studienanmeldedaten

Zuerst eingereicht

24. Januar 2008

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. Januar 2008

Zuerst gepostet (Schätzen)

30. Januar 2008

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

31. Juli 2019

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

29. Juli 2019

Zuletzt verifiziert

1. März 2010

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren